Skip to main content


Presenter: Hendrika Bootsma, University of Groningen, the Netherlands.

Wednesday 12 June: 16:15–17:45 (Abstract OP0045)

In the ASAP III trial, participants received abatacept for 48 weeks, or placebo for 24 weeks followed by abatacept for the remaining 24 weeks. The primary outcome measure is the same as that used in the IM101-603 trial: change in EULAR Sjögren's Syndrome Disease Activity Index from baseline to week 24.

More on this trial